Oncology Hematologic / Blood Related Cancers Lymphoma Non-Hodgkins Relapsed/Refractory Other
Categories
Protocols
NURIX-NX-5948-301 Phase I OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies